Brief: Alpha Healthcare Acquisition Announces Merger With Carmell Therapeutics, A Phase 2 Stage Biotechnology Platform Company

Longevity Health Holdings

05/01/2023 03:16

Jan 4 (Reuters) - Alpha Healthcare Acquisition Corp Iii
 ALPA.O :
    * ALPHA HEALTHCARE ACQUISITION CORP. III ANNOUNCES MERGER
WITH
CARMELL THERAPEUTICS, A PHASE 2 STAGE BIOTECHNOLOGY PLATFORM
COMPANY DEVELOPING ALLOGENEIC PLASMA-BASED BIOMATERIALS FOR BONE
AND SOFT TISSUE HEALING INDICATIONS
    * MR. RANDY HUBBELL WILL SERVE AS CHIEF EXECUTIVE OFFICER OF
COMBINED COMPANY
    * COMBINED CO EXPECTED TO RECEIVE GROSS PROCEEDS OF ABOUT
$154
MILLION AT CLOSING OF DEAL ASSUMING NO REDEMPTIONS
    * UPON CLOSING OF THE TRANSACTION, ALPA WILL BE RENAMED
CARMELL
THERAPEUTICS CORPORATION
    * COMBINED COMPANY'S COMMON STOCK IS EXPECTED TO BE LISTED
ON
NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL "CTCX."
    * ALPHA HEALTHCARE ACQUISITION CORP - CARMELL'S SHAREHOLDERS
WILL
RECEIVE AGGREGATE 15 MILLION SHARES OF ALPA IN EXCHANGE FOR
EXISTING CARMELL SHARES
    * ALPHA HEALTHCARE ACQUISITION CORP - CARMELL SHAREHOLDERS
WILL
RECEIVE AGGREGATE 15 MILLION SHARES OF ALPA'S CLASS A STOCK IN
EXCHANGE FOR CARMELL SHARES

Source text for Eikon:  ID:nBw5JnDC7a 
Further company coverage:  ALPA.O 
 ((Reuters.Briefs@thomsonreuters.com;))